

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



ASCENTAGE PHARMA GROUP INTERNATIONAL

亞盛醫藥集團

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 6855)

Voluntary Announcement

Approvals Obtained in China and U.S. for Three Phase Ib/II Clinical Trials of APG-2575

Ascentage Pharma Group International (the “**Company**”) is pleased to announce that it has received approvals in the U.S and China for Phase Ib/II clinical trials of APG-2575, a novel Bcl-2 selective inhibitor being developed by the Company.

APG-2575 is a novel, orally administered Bcl-2 selective inhibitor being developed by the Company. The Phase I trial of APG-2575 in hematological malignancies is ongoing in the U.S. and Australia. APG-2575 is also the first China-made Bcl-2 selective inhibitor to enter clinical trials in China. Thus far, no dose-limiting toxicity (DLT) or tumor lysis syndrome (TLS) that is commonly associated with Bcl-2 inhibitors, was observed in the trial, implicating APG-2575’s potential favorable safety profile. For efficacy, as of August 13, 2019, one CLL/SLL patient in the trial reached the criteria for partial response (PR) and three CLL patients achieved normal absolute lymphocyte counts (ALC) within the first treatment cycle. (For preliminary efficacy data of APG-2575, please refer to the prospectus of Company dated October 16, 2019)

The two clinical studies approved by U.S. Food and Drug Administration (FDA) include one Phase Ib/II trial of APG-2575 as a single agent or in combination with rituximab/acalabrutinib for the treatment of relapsed/refractory chronic lymphocytic leukemia (r/r CLL) or small lymphocytic lymphoma (r/r SLL); and one Phase Ib/II trial of APG-2575 as a single agent or in combination with ibrutinib/rituximab for the treatment of Waldenström macroglobulinemia (WM). Furthermore, following the recent approval from the Center for Drug Evaluation (CDE) of China National Medical Products Administration (NMPA), the company is poised to initiate a Phase Ib trial of APG-2575 as a single agent or in combination for the treatment of relapsed/refractory acute myeloid leukemia (r/r AML) in China.

The Company believes that the approvals for the three Phase Ib/II trials of APG-2575 are based on satisfactory preclinical and early-stage clinical data. The Company will actively carry forward the product's clinical studies globally, in hope of providing benefits for the patients soon.

Cautionary Statement required by Rule 18A.05 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited: We cannot guarantee that we will be able to obtain further approval for, or ultimately market, APG-2575 successfully.

By order of the Board
Ascentage Pharma Group International
Dr. Yang Dajun
Chairman and Executive Director

Suzhou, People's Republic of China, March 9, 2020

As at the date of this announcement, the Board of Directors of the Company comprises Dr. Yang Dajun as Chairman and executive Director, Dr. Wang Shaomeng, Dr. Tian Yuan, Mr. Zhao Qun, Dr. Lu Simon Dazhong and Mr. Liu Qian as non-executive Directors, and Mr. Ye Changqing, Dr. Yin Zheng and Mr. Ren Wei as independent non-executive Directors.